These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9225949)

  • 1. Pharmacokinetics of intrapericardial administration of 5-fluorouracil.
    Lerner-Tung MB; Chang AY; Ong LS; Kreiser D
    Cancer Chemother Pharmacol; 1997; 40(4):318-20. PubMed ID: 9225949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A case of malignant pericardial effusion due to breast cancer successfully controlled by intrapericardial chemotherapy using pirarubicin].
    Fujito T; Maeura Y; Shimoda M; Hojo S; Yano Y; Matsunaga S
    Gan To Kagaku Ryoho; 2001 Oct; 28(11):1757-9. PubMed ID: 11708027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
    Klaassen U; Wilke H; Seeber S
    J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrapericardial administration of cisplatin in treatment of metastatic pericardial involvement in adenocarcinoma of the lung.
    Tomkowski WZ; Filipecki S
    Monaldi Arch Chest Dis; 1997 Jun; 52(3):221-4. PubMed ID: 9270245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlling malignant pericardial effusion by intrapericardial carboplatin administration in patients with primary non-small-cell lung cancer.
    Moriya T; Takiguchi Y; Tabeta H; Watanabe R; Kimura H; Nagao K; Kuriyama T
    Br J Cancer; 2000 Oct; 83(7):858-62. PubMed ID: 10970685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrapericardial cisplatin for the management of patients with large malignant pericardial effusion in the course of the lung cancer.
    Tomkowski WZ; Filipecki S
    Lung Cancer; 1997 Mar; 16(2-3):215-22. PubMed ID: 9152952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
    Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of intrapericardial cisplatin administration in cases of recurrent malignant pericardial effusion and cardiac tamponade].
    Tomkowski W; Szturmowicz M; Borowiec B; Burakowski J; Fijałkowska A; Kober J; Filipecki S
    Pneumonol Alergol Pol; 1996; 64 Suppl 2():180-6. PubMed ID: 9181888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer.
    Oman M; Lundqvist S; Gustavsson B; Hafström LO; Naredi P
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):603-9. PubMed ID: 16047145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intrapericardial infusion of etoposide and cisplatin in treating malignant pericardial effusion of non-small cell lung cancer].
    Chen LK; Xu GC; Liang Y; Yang QY; Zhang LN
    Ai Zheng; 2006 Apr; 25(4):505-8. PubMed ID: 16613690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
    Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
    Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrapericardial instillation of cisplatin in a patient with a large malignant effusion.
    Markman M; Howell SB
    Cancer Drug Deliv; 1985; 2(1):49-52. PubMed ID: 4052925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
    Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
    Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
    Guo XD; Harold N; Saif MW; Schuler B; Szabo E; Hamilton JM; Monahan BP; Quinn MG; Cliatt J; Nguyen D; Grollman F; Thomas RR; McQuigan EA; Wilson R; Takimoto CH; Grem JL
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):79-85. PubMed ID: 12707718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant pericardial effusion secondary to ovarian adenocarcinoma: a case report.
    Micha JP; Goldstein BH; Zusman D; Rettenmaier MA; Epstein HD; Brown JV
    J Reprod Med; 2007 Oct; 52(10):971-3. PubMed ID: 17977179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
    Ychou M; Duffour J; Kramar A; Debrigode C; Gourgou S; Bressolle F; Pinguet F
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):282-90. PubMed ID: 12827293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New approaches to the management and treatment of malignant pericardial effusion.
    Tomkowski W; Szturmowicz M; Fijałkowska A; Burakowski J; Filipecki S
    Support Care Cancer; 1997 Jan; 5(1):64-6. PubMed ID: 9010992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.